Liquid biopsies are becoming increasingly important for the detection of actionable mutations in cancer due to tumor heterogeneity as well as the practical limitations of invasive tissue biopsies. Recent technological developments enable the use of circulating tumor DNA (ctDNA) as cancer biomarkers as a non-invasive complement and potentially even substitute for tissue biopsies.

This webinar discusses the current research applications of ctDNA in cancer detection with potential for improved therapy guidance and monitoring. Critical challenges impeding liquid biopsy analysis and ways to overcome these challenges will also be discussed.